Immune Design Corp. (NASDAQ:IMDZ) shares traded down 3% during trading on Friday . The stock traded as low as $7.54 and last traded at $7.66, with a volume of 87,841 shares. The stock had previously closed at $7.90.

A number of research analysts recently issued reports on the company. Jefferies Group restated a “buy” rating and set a $20.00 price objective on shares of Immune Design Corp. in a research report on Sunday, May 29th. Cowen and Company restated an “outperform” rating on shares of Immune Design Corp. in a research report on Wednesday, April 27th. Leerink Swann restated a “buy” rating on shares of Immune Design Corp. in a research report on Thursday, May 12th. Zacks Investment Research lowered Immune Design Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, July 12th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a research report on Wednesday, May 11th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $24.00.

The firm’s 50 day moving average is $8.22 and its 200 day moving average is $11.19. The firm’s market cap is $154.57 million.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.01. On average, analysts expect that Immune Design Corp. will post ($2.70) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Immune Design Corp. stock. Jennison Associates raised its stake in Immune Design Corp. (NASDAQ:IMDZ) by 0.6% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 202,683 shares of the company’s stock after buying an additional 1,224 shares during the period. Jennison Associates owned about 1.01% of Immune Design Corp. worth $2,473,000 at the end of the most recent quarter.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.